VCAM-targeted delivery of recombinant CD39 to the endothelium is antithrombotic, antiinflammatory and ameliorates ischaemia reperfusion injury

Project: Research

Project Details

StatusFinished
Effective start/end date1/01/1531/12/18

Funding

  • National Health and Medical Research Council (NHMRC) (Australia): AUD603,813.00